Form 4: Profusa Director Lauren Chung Receives Stock Options

Profusa, Inc. Director Lauren Chung was granted 274,660 stock options with an exercise price of $0.35, vesting over one to three years.

Summary

• Lauren Chung, a Director of Profusa, Inc. (PFSA), acquired 274,660 derivative securities in the form of stock options.
• The options have an exercise price of $0.35 per share.
• An inaugural director award of 221,794 options vests in three equal annual increments over a period of three years from the closing of the business combination between NorthView Acquisition Corp. and Profusa, Inc. (the "Closing").
• An annual director award of 52,866 options vests on the first anniversary of the Closing.
• All options have an expiration date of January 26, 2036.
• The underlying security for these options is Profusa, Inc. Common Stock.

Sentiment

Score: 6

Explanation: This is a routine insider transaction reporting an equity grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns interests, but does not convey new operational or financial performance information.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options provide a potential future upside for the director, contingent on the company's stock price appreciation above the exercise price of $0.35.

Negatives

• The options do not represent immediate cash value and their ultimate value is dependent on future stock performance.
• The vesting schedules mean the director must remain with the company for a period to fully realize the awards.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Profusa, Inc.'s common stock.
• If the company's stock price does not rise above the exercise price of $0.35, the options may expire worthless.

Future Outlook

The granting of stock options to a director is a forward-looking incentive, aiming to motivate the director to contribute to the company's long-term growth and increase shareholder value, as the options' value is tied to future stock price appreciation.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and medical device industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotechnology and medical devices.
• The specific number of options and vesting schedule are typical for incentivizing long-term commitment and performance, though direct comparisons to specific companies or projects are not provided in the filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to Lauren Chung, a Director of Profusa, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting employees, a well-compensated and incentivized board can contribute to overall company stability and strategic direction, indirectly benefiting employees.

Next Steps

• The options will vest according to their respective schedules, contingent on the director's continued service.
• The director may choose to exercise the vested options at any time before their expiration date, subject to company policy and market conditions.

Key Dates

Keywords

Profusa, PFSA, Lauren Chung, stock options, director compensation, SEC Form 4, insider transaction, equity award, vesting